Clinical Trial Detail

NCT ID NCT03809624
Title Study of INBRX-105 in Patients With Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma (PDL1x41BB)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Inhibrx, Inc.
Indications

renal cell carcinoma

lung non-small cell carcinoma

melanoma

gastric adenocarcinoma

Hodgkin's lymphoma

Advanced Solid Tumor

non-Hodgkin lymphoma

transitional cell carcinoma

gastroesophageal junction adenocarcinoma

head and neck squamous cell carcinoma

Therapies

INBRX-105

Age Groups: adult senior

No variant requirements are available.